What was studied?
This double-blind, placebo-controlled trial randomized 1,106 adults with sepsis across 22 centers in China. The primary analysis included participants who received study treatment and assessed all-cause mortality at 28 days.
What did the researchers report?
Mortality was similar between groups: 23.4% with thymosin alpha 1 and 24.1% with placebo in the reported analysis. Secondary and safety outcomes did not differ significantly. The overall result did not support a clear mortality benefit.
What are the limits?
Subgroup signals should not replace the neutral overall outcome. This trial involved critically ill patients receiving standard medical care and a defined study product. It does not validate generalized immune-enhancement claims or research-supply materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.